

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Diagnostics Assessment Programme

Tumour profiling tests to guide adjuvant chemotherapy decisions in lymph node-positive early breast cancer' (provisional title)

Provisional stakeholder list

<p>Manufacturers Agendia N.V. Exact Sciences UK Ltd Myriad International GmbH Veracyte Inc.</p>
<p>Professional groups Association of Breast Surgery Association of Genetic Nurses and Counsellors British Oncology Pharmacy Association Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society The London Breast Clinic UK Breast Cancer Group (UKBCG)</p>
<p>Patient/carer groups Breast Cancer Care Breast Cancer Now Breast Cancer UK Cancer Black Care Cancer Care Cancer Equality Cancer Research UK Helen Rollason Cancer Charity Independent Cancer Patients Voice Macmillan Cancer Support Maggie's Centres Marie Curie METUP UK Tenovus Cancer Care</p>
<p>Industry Associations ABHI BIVDA</p>
<p>Research groups Peony Breast Cancer Unit Institute for Cancer Research Newcastle upon Tyne Hospital NHS Trust (NUTH)</p>
<p>Associated guideline groups British Association of Surgical Oncology National Cancer Research Institute Scottish Intercollegiate Guidelines Network</p>

/continued

External Assessment Group School of Health and Related Research (SchARR)
Others Allied Health Professionals Federation Department of Health and Social Care Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare Products Regulatory Agency (MHRA) NHS Confederation NHS England Northern Ireland Cancer Network Welsh Government Illumina

Please note, all organisations in the list of provisional stakeholders have been invited to participate or have already registered.

Definitions:

Stakeholders

Individuals or organisations interested in a topic being evaluated by the Diagnostics Assessment Programme, and who register to become a stakeholder. For example, manufacturers of the technology, national organisations that represent healthcare professions who operate or use the results of the technology, national patient or carer organisations, NHS service providers and commissioners, statutory organisations and research organisations.

External Assessment Group (EAG)

An independent academic group commissioned by the NIHR Evaluation, Trials and Studies Coordinating Centre (NETSCC) that prepares a systematic review of the clinical and cost effectiveness of the technologies.